NDAORALTABLET
Approved
Aug 2014
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
5
Mechanism of Action
Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Clinical Trials (5)
A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants
Started May 2021
33 enrolled
HIV Infections
To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers
Started Feb 2018
36 enrolled
HIV Infections
Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs
Started Nov 2016
33 enrolled
Human Immunodeficiency Virus
Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations
Started Nov 2015
27 enrolled
HIV Infections
Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany
Started Feb 2015
403 enrolled
HIV Infections
Loss of Exclusivity
LOE Date
Jun 8, 2030
51 months away
Patent Expiry
Jun 8, 2030
Exclusivity Expiry
Dec 15, 2026
Patent Records (4)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8129385 | Oct 5, 2027 | SubstanceProduct | — |
| 8129385*PED | Apr 5, 2028 | — | |
| 9242986 | Dec 8, 2029 | SubstanceProduct | — |
| 9242986*PED | Jun 8, 2030 | — |